Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI9197 (Telratolimod) Monotherapy and Combination in Solid Tumors
NCT02556463Phase 1Terminated
- Sponsor
- MedImmune
- Start
- Nov 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of telratolimod in solid tumor and cutaneous T-cell lymphoma (CTCL) (4 arms), sponsored by MedImmune. Primary endpoints: Safety and tolerability as determined by assessment of dose limiting toxicities and the maximum tolerated dose or maximal assessed dose per protocol of MEDI9197 when administered by intratumoral…, Safety and tolerability as determined by assessment of dose limiting toxicities and the maximum tolerated dose or maximal assessed dose per protocol of MEDI9197 when administered by intratumoral… and 1 more. Started Nov 2015; status: terminated.
02
Drugs
telratolimod
03
Conditions
solid tumorcutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT02556463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02556463.